October 14, 2021 7:54am
Three (3) sector positive closes in a row, 5 five (5) positive closes out of nine (9) sessions
News: Brainstorm Cell therapeutics (BCLI +$0.23 or +7.10% pre-market indication). On news of presenting findings from a multicenter, open label clinical trial of NurOwn® in progressive multiple sclerosis.
Pre-open indications: 4 BUYs, 1 SELL and 1 Pump (or No Promote)
What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity! My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.75% (+256 points), S&P futures are UP +0.80% (+35 point) and NASDAQ futures are UP +0.87% (+128 point)
U.S. stock futures were climbing higher on Thursday
European stocks advanced reflecting on the latest inflation data and earnings out of the U.S.,
Asia-Pacific stocks were mostly higher as investors reacted to the release of Chinese inflation data for September which showed the producer price index for September soared 10.7%
Henry’omics:
The stock market rally attempt ended with slim to solid gains Wednesday, but the best was that the indexes finally closed near session highs.
Minutes released Wednesday afternoon from the Federal Open Market Committee’s September meeting showed the central bank could begin tapering its asset-purchase program as soon as mid-November.
Economic data Docket: September producer price index data and weekly jobless claims
If you didn’t remember what happen at Wednesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Wednesday’s evening’s recap: “a broad-brush approach and sector review, Up, down, round and round.” … https://www.regmedinvestors.com/articles/12137
Q4: October, 5 positive and 4 negative closes
Q3/21:
- September, 1 holiday, 10 positive and 10 negative close
- August - 12 positive and 10 negative close
- July: 6 positives, 1 holiday and 15 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
SELL with a Pump or no promote:
Biostage (BSTG) closed up =$0.09 with 3,492 shares traded – WOW after Tuesday’s -$0.20 to $3.01 with 614 shares traded after Monday’s flat after Friday’s $0.00 (flat) with 32 shares traded following Thursday’s +$0.19 to $3.21 with 612 shares. For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation. What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
BUY:
Brainstorm Cell therapeutics (BCLI) closed up +$0.01 to $3.15 with a positive +$0.23 or +7.10% pre-market indication. On news of presenting findings from a multicenter, open label clinical trial of NurOwn® in progressive multiple sclerosis. The P 2 clinical trial was designed to evaluate intrathecal administration of NurOwn (autologous MSC-NTF cells) in participants with progressive MS. The study achieved the primary endpoint of safety and tolerability. It demonstrated a reduction of neuroinflammatory biomarkers and an increase in neuroprotective biomarkers in the cerebrospinal fluid (CSF) and consistent improvement across MS functional outcome measures, including measures of walking, upper extremity function, vision and cognition.
Cellectis SA (CLLS) closed up +$0.47 to $9.62 with a positive +$0.36 or +3.74% pre-open indication.
Editas Medicine (EDIT) closed up =$0.34 to $37.87 with a positive +$0.53 or +1.40% pre-market indication.
Fate Therapeutics (FATE) closed up +$1.08 to $60.15 after Tuesday’s +$2.52 to $59.07 with a positive +$1.35 or +2.24% aftermarket indication.
SELL into Strength:
Vericel (VCEL) closed up +$1.16 to $49.43 with a positive +$0.10 or +0.20% pre-market indication.
The BOTTOM LINE: I am STILL NOT taking any action until the stem cell and gene therapy sector movement's direction is confirmed - my usual timing is 10 to 10:20 a.m.
My theme is skepticism … trust should nt be a factor aftet multiple "up" sesssions.
Sector stocks have traded choppily over the past several weeks as investors contemplated the implications of ongoing price increases (i.e., inflation) against a backdrop of decelerating economic growth.
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
